NCT06482905 2026-01-06
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Tcelltech Inc.
Phase 1 Recruiting
Tcelltech Inc.
Tcelltech Inc.
Suzhou Immunofoco Biotechnology Co., Ltd
Shenzhen Celconta Life Science Co., Ltd.
Shanghai AbelZeta Ltd.